Adverum Biotechnologies Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Adverum Biotechnologies şirketinin kazançları yıllık ortalama -6.9% oranında azalırken, Biotechs sektörünün kazançları yıllık 7.7% oranında artan oldu. Gelirler yıllık ortalama 1.2% oranında artan oldu.

Anahtar bilgiler

-6.9%

Kazanç büyüme oranı

3.2%

EPS büyüme oranı

Biotechs Sektör Büyümesi	-14.6%
Gelir büyüme oranı	1.2%
Özkaynak getirisi	-65.3%
Net Marj	-9,411.1%
Son Kazanç Güncellemesi	30 Sep 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Adverum Biotechnologies nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:AVU0 Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Sep 24	1	-94	36
30 Jun 24	0	-100	40
31 Mar 24	0	-113	48
31 Dec 23	4	-117	50
30 Sep 23	4	-126	48
30 Jun 23	4	-133	51
31 Mar 23	4	-146	52
31 Dec 22	0	-155	55
30 Sep 22	0	-156	57
30 Jun 22	0	-154	54
31 Mar 22	0	-155	62
31 Dec 21	8	-146	63
30 Sep 21	8	-149	66
30 Jun 21	8	-138	63
31 Mar 21	8	-123	52
31 Dec 20	0	-118	45
30 Sep 20	0	-99	39
30 Jun 20	0	-87	35
31 Mar 20	0	-73	32
31 Dec 19	0	-64	28
30 Sep 19	0	-61	25
30 Jun 19	1	-66	23
31 Mar 19	1	-70	25
31 Dec 18	2	-73	25
30 Sep 18	2	-72	22
30 Jun 18	2	-65	23
31 Mar 18	2	-57	18
31 Dec 17	2	-56	20
30 Sep 17	2	-64	22
30 Jun 17	2	-64	22
31 Mar 17	2	-114	20
31 Dec 16	1	-114	20
30 Sep 16	2	-105	19
30 Jun 16	2	-105	20
31 Mar 16	2	-53	23
31 Dec 15	2	-47	20
30 Sep 15	2	-44	20
30 Jun 15	1	-38	15
31 Mar 15	1	-36	11
31 Dec 14	1	-29	8
30 Sep 14	0	-22	5
30 Jun 14	0	-14	3
31 Mar 14	0	-7	2
31 Dec 13	0	-5	1

Kaliteli Kazançlar: AVU0 şu anda kârlı değil.

Büyüyen Kar Marjı: AVU0 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: AVU0 kârlı değildir ve zararlar son 5 yılda yılda 6.9% oranında artmıştır.

Büyüme Hızlandırma: AVU0 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: AVU0 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -21.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: AVU0 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -65.3% ) sahiptir.

Adverum Biotechnologies Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half earnings released

Recent updates

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

Adverum Biotechnologies, Inc. Appoints Linda Rubinstein as Chief Financial Officer

Adverum Biotechnologies, Inc. Announces New Data from the OPTIC Study Treating Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet Age-Related Macular Degeneration

Adverum Biotechnologies, Inc. Presents Best-Corrected Visual Acuity and Central Subfield Thickness Analyses After A Single IVT Injection of ADVM-022 (Ixo-vec) in the OPTIC Study in Wet AMD

Adverum Biotechnologies Announces Upcoming Data Presentation at ASRS 2022

Adverum Biotechnologies, Inc. Completes IND Amendment and Prepares to Initiate Phase 2 LUNA Trial of ADVM-022 in Wet AMD

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 2000 Dynamic Index

Adverum Biotechnologies, Inc. Presents Three-Year Aflibercept Protein Expression and Improvement in Anatomic Outcomes After A Single IVT Injection of ADVM-022 in the Optic Study in Wet AMD

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies Announces New Data At the Macula Society's 2022 Annual Meeting

Adverum Biotechnologies Presents Research Pipeline Data Supporting Utility of Its Proprietary Platform and AAV.7m8 Capsid in Ocular Gene Therapy

Adverum Biotechnologies, Inc. Presents Data At American Society of Gene and Cell Therapy Further Supporting Phase 2 Development Plans for ADVM-022

Adverum Biotechnologies, Inc. Presents Additional Efficacy and Safety Data from the Optic Trial of ADVM-022 in Wet AMD At the ARVO 2022 Annual Meeting

High number of new directors

Adverum Biotechnologies, Inc. Appoints Richard Beckman M.D. as Chief Medical Officer

Adverum Biotechnologies, Inc. Grants Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy

Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022

Independent Director recently sold €95k worth of stock

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Adverum Biotechnologies, Inc. Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular Edema

Adverum Biotechnologies, Inc.(NasdaqGM:ADVM) dropped from Russell 3000E Growth Index

Independent Chairman recently bought €84k worth of stock

Lexeo Therapeutics, LLC Announces License Agreement with Adverum Biotechnologies, Inc

Adverum Biotechnologies, Inc. Appoints Reed V. Tuckson as an Independent Member to Board of Directors

Adverum Biotechnologies, Inc. Appoints Christopher J. Derespino as Chief Business Officer

Adverum Biotechnologies, Inc. Appoints Leone Patterson as Principal Financial Officer and Principal Accounting Officer

Independent Chairman recently bought €95k worth of stock

Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME

New 90-day low: €8.70

Adverum Biotechnologies, Inc Appoints Dawn Svoronos as Independent Member of Board of Directors

New 90-day high: €11.90

Adverum Biotechnologies, Inc. Announces Positive Interim Data from Cohorts 1-4 from Optic Phase 1 Trial of Advm-022 Intravitreal Gene Therapy for Wet AMD

Revenue misses expectations

New 90-day low: €9.45

Adverum Biotechnologies, Inc. Announces the Appointment of Christopher J. Morrison, as Vice President of Process Science

New 90-day low - €10.20

Adverum Biotechnologies, Inc. has completed a Follow-on Equity Offering in the amount of $188.5 million.

New 90-day low - €12.70

First half earnings released

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin